ABSTRACT
Although amyloid infiltration of the thyroid gland is an uncommon but well-known phenomenon, the appearance of a goiter secondary to amyloid deposits is rare. The goiter enlarges rapidly and progressively, often becoming compressive like thyroid cancer. The diagnosis is rarely suggested clinically even in the presence of known amyloidosis. We describe the case of a 45-year-old patient who presented an amyloid goiter as the first manifestation of systemic amyloidosis, probably secondary to bronchiectasis.
Subject(s)
Amyloidosis/diagnosis , Goiter/complications , Amyloidosis/diagnostic imaging , Amyloidosis/pathology , Amyloidosis/therapy , Colchicine/therapeutic use , Female , Goiter/diagnostic imaging , Goiter/drug therapy , Goiter/pathology , Humans , Middle Aged , Thyroid Gland/pathology , Thyroxine/therapeutic use , UltrasonographyABSTRACT
We report the case of a thyroiditis in a 44-year-old woman with relapsing-remitting multiple sclerosis treated with interferon beta. Before treatment, thyroid function tests were normal and anti-thyroid (anti-thyroglobulin and anti-thyroid peroxidase) antibodies were negative. After 18 months of treatment, the patient presented clinical features of thyroiditis. We noted a rise in TSH values and anti-thyroid antibodies were found positive. Treatment was not discontinued and further surveillance showed an improvement in clinical and biological features. We conclude that thyroid function should be monitored during INF beta treatment. Laboratory tests must be carried out before therapy. Clinical follow-up is indicated before undertaking biological tests.
